Did you know that March is National Head and Neck Cancer Awareness Month? The term ‘head and neck cancers’ refers to a type of tumor that begins in areas in and around the mouth, throat and nose. Taking healthy steps to reduce risk can prevent many head and neck cancers. Take a moment to raise your awareness of head and neck cancers. More than 55,000 new cases of head and neck cancers will be diagnosed in 2015, according to American Cancer Society.
Posts by Cedars-Sinai Oncology
March is National Colon & Rectum Cancer Awareness Month. This post is the first installment of a two part series to promote colorectal cancer awareness.
March is National Colon & Rectum Cancer Awareness Month. This is the second installment of a two part series to promote colorectal cancer awareness.
Receiving a diagnosis of colorectal cancer diagnosis is frightening. Dealing with a diagnosis of any cancer is a challenge and most patients find themselves feeling uncertain and afraid. Fortunately, resources and support are available to patients. Working with a multidisciplinary colorectal cancer treatment team, an informed patient can prepare for the journey ahead.
Women with advanced estrogen receptor-positive (ER-positive) breast cancer now have a new treatment option at their disposal. The FDA recently approved a drug called palbociclib (Ibrance®) as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.
This year at the San Antonio Breast Cancer Symposium (SABCS) there were two aspects of breast cancer that were clearly emphasized: use of ovarian suppression in premenopausal women with breast cancer and advances in genetic testing for hereditary cancer predisposition.
Results of the SOFT trial (further detailed by Dr. Wade Smith in this post), show a clear benefit to the addition of ovarian suppression in women under the age of 35. This benefit resembles that seen with the addition of Herceptin for HER2+ cancer, and now calls for a change in practice management.
Kadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer.
A major milestone was recently celebrated in the development of a 112,500-square-foot medical facility dedicated to multidisciplinary care and treatment for cancer patients in San Fernando Valley. On October 8, 2014, demolition began on the existing structure in Tarzana at the future site of the Integrated Cancer Institute.